UNITED THERAPEUTICS Corp 8-K, filed Sep 11, 2020
UNITED THERAPEUTICS Corp (UTHR)
About this 8-K
UNITED THERAPEUTICS Corp filed this 8-K on September 11, 2020, reporting on events of September 10, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 10, 2020, the Board of Directors (the “Board”) of United Therapeutics Corporation (the “Company”), acting upon the recommendation of its Nominating and Governance Committee, appointed Linda Maxwell, M.D., to serve as a member of the Board. Dr. Maxwell will serve as a Class I director, and her term will expire at the Company’s 2021 annual meeting of shareholders. The Board has determined that Dr. Maxwell will not serve on a Board committee initially. With the addition of Dr. Maxwell, the Board now comprises 12 directors, 11 of whom are independent.
In connection with Dr. Maxwell’s appointment to the Board, the Company awarded her 20,680 stock options under the Company’s Amended and Restated 2015 Stock Incentive Plan. These awards were granted on September 10, 2020, and the stock options have an exercise price equal to the closing price of the Company’s common stock as reported on the NASDAQ Global Select Market on that date. These awards were granted in accordance with the Company’s standard compensation program for non-employee directors (the “Director Compensation Program”), as described in the Company’s definitive proxy statement for its 2020 annual meeting of shareholders, filed with the Securities and Exchange Commission (“SEC”) on April 29, 2020. Dr. Maxwell will be provided further compensation for her services in accordance with the Director Compensation Program. Dr. Maxwell and the Company also entered into the Company’s standard indemnification agreement for directors and executive officers, effective September 10, 2020, the form of which was filed with the SEC as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009.
Item 7.01 Regulation FD Disclosure.
A copy of the press release announcing Dr. Maxwell’s appointment is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Exhibits
(d) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated September 11, 2020 | |
| 104 |
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | ||
| Dated: September 11, 2020 | By: | /s/ Paul A. Mahon |
| Name: | Paul A. Mahon | |
| Title: | General Counsel | |
3
Exhibit 99.1
For Immediate Release
UNITED THERAPEUTICS CORPORATION APPOINTS LINDA MAXWELL TO ITS BOARD OF DIRECTORS
SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., September 11, 2020 – United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell, M.D. to its Board of Directors as an independent director, effective as of September 10, 2020.
| Dr. Maxwell has been a head and neck surgeon since 2006, and is a medical educator, a published scientific author, and a health technology entrepreneur and innovator. | ![]() |
| Dr. Maxwell is Adjunct Professor of Surgery at the University of Toronto, Distinguished Visiting Professor at Ryerson University, and Associate Scientist at the Li Ka Shing Knowledge Institute in Toronto. She served as Founding and Executive Director of the Biomedical Zone in 2015 – Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies – and has guided a wide variety of startup companies through clinical development, capitalization, and commercialization. Dr. Maxwell also managed a life sciences tech transfer |
portfolio at the University of Oxford and the UK National Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert to various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee of the Public Health Agency of Canada, and as an advisor to the Canadian Medical Association and the Canadian Space Agency.
Dr. Maxwell earned an A.B. with honors from Harvard University, an M.D. from Yale University, and an M.B.A. from the University of Oxford. She serves as an independent member of the Board of Directors of Profound Medical Inc., a publicly-traded company listed both in the United States and Canada.
“We greatly value Dr. Maxwell’s outstanding achievements and experience,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “Her knowledge and business expertise position her well to serve on our Board of Directors.”
“I am thrilled to join the United Therapeutics family as an independent director,” said Dr. Maxwell. “It is a privilege to join an extraordinary organization tackling some of the most pernicious problems in medicine through scientific ingenuity, visionary leadership, and a singular commitment to advancing human health.“
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.
Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
| 1 | ||
Forward-looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, our ability to create value and sustain our success in the long-term, and our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 11, 2020, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: ir@unither.com
* * *
| 2 | ||
